

**Appendix 1: Supplementary tables [posted as supplied by author]**

**Table A.** Details of MeSH Search Terms

<b>Stent</b>	<b>MeSH terms</b>
Bare Metal Stent	Randomized controlled trial, clinical trial, Human, Diabetes, Bare metal stent, Vision, Bx velocity, Millenium, Multilink vision
Drug Eluting Stent	Randomized controlled trial, clinical trial, Human, Diabetes, Drug eluting stent, Eluting stent, Paclitaxel, Sirolimus, Everolimus, Zotarolimus

**Appendix Table B.** Sensitivity Analysis: Select Outcomes in Trials with Low-bias Risk

Reference	Comparator	TVR	Death	MI	Any ST
		RR (95% Cr I)	RR (95% Cr I)	RR (95% Cr I)	RR (95% Cr I)
Bare Metal	Sirolimus	0.37 (0.28, 0.46)	0.99 (0.72, 1.36)	0.75 (0.51, 1.03)	0.67 (0.34, 1.35)
	Paclitaxel	0.47 (0.35, 0.62)	1.01 (0.67, 1.44)	0.80 (0.52, 1.14)	0.83 (0.37, 1.69)
	Everolimus	0.30 (0.18, 0.45)	0.88 (0.42, 1.56)	0.49 (0.20, 0.94)	0.58 (0.18, 1.62)
	Zotarolimus	0.60 (0.40, 0.93)	1.20 (0.62, 2.26)	2.52 (0.92, 7.01)	3.61 (0.81, 19.51)
Sirolimus	Paclitaxel	1.26 (1.00, 1.68)	1.01 (0.70, 1.39)	1.08 (0.72, 1.53)	1.19 (0.63, 2.43)
	Everolimus	0.81 (0.54, 1.17)	0.88 (0.45, 1.56)	0.64 (0.28, 1.24)	0.85 (0.32, 2.21)
	Zotarolimus	1.61 (1.12, 2.47)	1.22 (0.65, 2.16)	3.33 (1.30, 8.41)	5.35 (1.40, 31.05)
Paclitaxel	Everolimus	0.63 (0.41, 0.91)	0.87 (0.44, 1.44)	0.61 (0.28, 1.12)	0.71 (0.26, 1.70)
	Zotarolimus	1.28 (0.85, 1.94)	1.18 (0.62, 2.34)	3.12 (1.19, 8.01)	4.32 (1.18, 23.58)
Everolimus	Zotarolimus	2.00 (1.24, 3.61)	1.37 (0.64, 3.34)	5.28 (1.68, 15.84)	6.16 (1.29, 40.22)

Cr I = credibility interval; MI = myocardial infarction; ST = stent thrombosis; TVR= target vessel revascularization

**Appendix Table C. Sensitivity Analysis: Select Outcomes in Non-ACS Trials**

Reference	Comparator	TVR	Death	MI	Any ST
		RR (95% Cr I)	RR (95% Cr I)	RR (95% Cr I)	RR (95% Cr I)
Bare Metal	Sirolimus	0.33 (0.22, 0.46)	0.94 (0.60, 1.45)	0.64 (0.38, 1.02)	0.61 (0.16, 1.84)
	Paclitaxel	0.41 (0.27, 0.57)	0.92 (0.57, 1.43)	0.69 (0.40, 1.13)	0.87 (0.25, 3.01)
	Everolimus	0.26 (0.14, 0.43)	0.79 (0.35, 1.66)	0.42 (0.13, 0.90)	0.54 (0.10, 2.59)
	Zotarolimus	0.71 (0.38, 1.28)	1.27 (0.53, 2.97)	5.52 (1.08, 74.24)	7.41 (0.53, 130.50)
Sirolimus	Paclitaxel	1.21 (0.91, 1.63)	0.98 (0.66, 1.40)	1.07 (0.69, 1.65)	1.41 (0.69, 3.81)
	Everolimus	0.79 (0.48, 1.19)	0.84 (0.42, 1.55)	0.65 (0.23, 1.29)	0.86 (0.27, 3.18)
	Zotarolimus	2.12 (1.20, 3.85)	1.35 (0.61, 2.93)	8.44 (1.93, 126.7)	11.36 (1.53, 171.30)
Paclitaxel	Everolimus	0.65 (0.38, 0.98)	0.86 (0.44, 1.56)	0.61 (0.22, 1.14)	0.62 (0.16, 2.02)
	Zotarolimus	1.74 (0.95, 3.16)	1.39 (0.57, 3.04)	8.04 (1.71, 106.3)	7.99 (0.91, 120.1)
Everolimus	Zotarolimus	2.67 (1.37, 5.76)	1.60 (0.58, 4.33)	13.52 (2.58, 240.5)	12.80 (1.29, 256.00)

ACS = acute coronary syndromes; Cr I = credibility interval; MI = myocardial infarction; ST = stent thrombosis; TVR= target vessel revascularization

**Appendix Table D.** Direct comparison analysis for select outcomes (Random effects model)

Treatment	Control	TVR	Death	MI	Any ST	Def/Prob ST
		RR (95% CI)	RR (95% CI)	RR (95% CI)	RR (95% CI)	RR (95% CI)
Sirolimus	Bare Metal	0.41 (0.31, 0.54)	1.09 (0.78, 1.51)	0.79 (0.54, 1.15)	0.79 (0.41, 1.53)	0.80 (0.32, 2.02)
Paclitaxel	Bare Metal	0.55 (0.41, 0.73)	0.91 (0.60, 1.37)	0.78 (0.51, 1.20)	0.75 (0.33, 1.69)	0.69 (0.24, 1.94)
Everolimus	Bare Metal	-	-	-	-	-
Zotarolimus	Bare Metal	0.50 (0.23, 1.06)	-	-	-	-
Paclitaxel	Sirolimus	1.15 (0.87, 1.52)	1.05 (0.78, 1.42)	1.28 (0.85, 1.93)	1.22 (0.64, 2.30)	1.08 (0.24, 4.90)
Everolimus	Sirolimus	0.70 (0.47, 1.04)	0.43 (0.20, 0.94)	0.16 (0.03, 0.90)	0.67 (0.24, 1.88)	0.51 (0.13, 2.09)
Zotarolimus	Sirolimus	2.01 (0.97, 4.14)	1.28 (0.74, 2.22)	3.35 (0.88, 12.67)	2.71 (0.60, 12.21)	1.02 (0.06, 16.26)
Everolimus	Paclitaxel	0.86 (0.63, 1.17)	1.36 (0.80, 2.31)	0.86 (0.55, 1.34)	0.79 (0.39, 1.61)	0.79 (0.39, 1.61)
Zotarolimus	Paclitaxel	1.08 (0.67, 1.75)	0.81 (0.15, 4.40)	1.84 (0.43, 7.89)	4.06 (0.68, 24.43)	2.94 (0.31, 28.04)
Zotarolimus	Everolimus	-	-	-	-	-

CI = confidence interval; MI = myocardial infarction; ST = stent thrombosis; TVR= target vessel revascularization

**Appendix Table E.** Between trial heterogeneity: Estimates of the between-trial variance  $\tau^2$

<b>Outcome</b>	<b><math>\tau^2</math> (Overall Model)</b>	<b><math>\tau^2</math> (Model Restricted to Low-Bias Risk Trials)</b>	<b><math>\tau^2</math> (Model Restricted to Trials with Clopidogrel &gt;6 m)</b>
Target Vessel Revascularization	0.03	0.03	0.05
Target Lesion Revascularization	0.08	0.11	0.13
Death	0.03	0.04	0.01
Myocardial Infarction	0.04	0.03	0.04
Any Stent Thrombosis	0.06	0.12	0.09
Definite Stent Thrombosis	0.19	0.39	0.21
Definite or Probable Stent Thrombosis	0.11	0.12	0.19

A  $\tau^2$  estimate of 0.04 is interpreted as a low, 0.14 as a moderate and 0.40 as a high degree of heterogeneity between trials.

**Appendix Table F.** Evaluation of model fit: Network of all trials

<b>Outcome</b>	<b>N of Data Points</b>	<b>Mean of residual deviance</b>	<b>N (%) of residuals within <math>\pm 1.96</math> of SND</b>	<b>Satisfactory Q-Q plot</b>
Target Vessel Revascularization	76	86	76 (100%)	Yes
Target Lesion Revascularization	76	87	76 (100%)	Yes
Death	70	66	69 (98.6%)	Yes
Myocardial Infarction	72	73	72 (100%)	Yes
Any Stent Thrombosis	72	58	71 (98.6%)	Yes
Definite Stent Thrombosis	66	48	65 (98.5%)	Yes
Definite or Probable Stent Thrombosis	76	54	76 (100%)	Yes

The model was considered to provide an adequate fit to the data if (i) the mean of the residual deviance was similar to the number of data points used in the model, (ii) at least 95% of means of standardized nodebased residuals were within  $\pm 1.96$  of the standard normal distribution, and (iii) Q-Q plots of residuals lied closely around a line on visual inspection. SND, Standard Normal Distribution

**Appendix Table G.** Evaluation of model fit: Model restricted to trials with low bias risk

<b>Outcome</b>	<b>N of Data Points</b>	<b>Mean of residual deviance</b>	<b>N (%) of residuals within <math>\pm 1.96</math> of SND</b>	<b>Satisfactory Q-Q plot</b>
Target Vessel Revascularization	66	77	66 (100%)	Yes
Target Lesion Revascularization	66	76	66 (100%)	Yes
Death	68	61	67 (98.5%)	Yes
Myocardial Infarction	62	61	62 (100%)	Yes
Any Stent Thrombosis	64	51	63 (98.4%)	Yes
Definite Stent Thrombosis	58	41	57 (98.3%)	Yes
Definite or Probable Stent Thrombosis	68	47	68 (100%)	Yes

The model was considered to provide an adequate fit to the data if (i) the mean of the residual deviance was similar to the number of data points used in the model, (ii) at least 95% of means of standardized nodebased residuals were within  $\pm 1.96$  of the standard normal distribution, and (iii) Q-Q plots of residuals lied closely around a line on visual inspection. SND, Standard Normal Distribution

**Appendix Table H.** Evaluation of model fit: Model restricted to trials with clopidogrel duration >6 months

<b>Outcome</b>	<b>N of Data Points</b>	<b>Mean of residual deviance</b>	<b>N (%) of residuals within <math>\pm 1.96</math> of SND</b>	<b>Satisfactory Q-Q plot</b>
Target Vessel Revascularization	64	73	64 (100%)	Yes
Target Lesion Revascularization	64	72	64 (100%)	Yes
Death	62	58	61 (98.4%)	Yes
Myocardial Infarction	62	64	62 (100%)	Yes
Any Stent Thrombosis	56	52	55 (98.2%)	Yes
Definite Stent Thrombosis	54	40	53 (98.2%)	Yes
Definite or Probable Stent Thrombosis	62	47	62 (100%)	Yes

The model was considered to provide an adequate fit to the data if (i) the mean of the residual deviance was similar to the number of data points used in the model, (ii) at least 95% of means of standardized nodebased residuals were within  $\pm 1.96$  of the standard normal distribution, and (iii) Q-Q plots of residuals lied closely around a line on visual inspection. SND, Standard Normal Distribution